GENE ONLINE|News &
Opinion
Blog

FDA
FDA
Weekly Cover:Foundation Medicine and Chugai Partnership with National Cancer Center
2020-02-18
Weight-Management Drug Belviq Withdraws from US Market
2020-02-14
Trevena Inc. Gives Oliceridine Approval Another Shot
2020-02-11
FDA Issues Guidances Supporting Development of Gene Therapy Products
2020-02-02
Ubrelvy Approval, the Best New Year Gift for CGRP Migraine Victims
2020-01-09
The Rejuvenated Promise of RNA Therapeutics
2020-01-07
Combating Clostridium difficile infections using Fecal Microbiota Transplant
2019-12-02
Clean Meat- from Petri Plate to Dinner Plate
2019-11-05
FDA’s Advisory Committee Recommends Palforzia’s approval for Peanut Allergy Treatment
2019-09-27
Rozlytrek Becomes the Third Tumor-Agnostic Medicine to be Approved by the USFDA
2019-08-21
Lynparza Meets Primary Endpoint in Phase III PROfound Trial
2019-08-16
Weekly in Asia 20190526-0601
2019-06-05
FDA Okays Expensive Gene Therapy for Infantile-Onset Spinal Muscular Atrophy
2019-05-29
Kisqali Fulvestrant Combo Rejected by NICE for Breast Cancer Treatment in the UK
2019-05-02
Erdafitinib Approval,a Bright Spot Amid the Troughs in Bladder Cancer Trials
2019-04-23
1 20 21 22 23 24
LATEST
UC Riverside Scientists Unveil RNA-based Vaccine Strategy, Potentially Avoiding Endless Booster Shots
2024-05-02
Lilly’s Q1 2024 Financial Report: Full-Year Revenue Outlook Raised by $2 Billion, with a 67% Net Income Increase
2024-05-02
Taiwan Breakthrough: Next-Generation Sequencing Now Covered in Health Insurance, Benefitting 20,000 Cancer Patients Annually
2024-05-02
CellTech Accelerator and Cyto-Facto Inc. Forge Strategic Partnership to Advance CGT Industry Growth
2024-04-29
Kaiser’s Data Breach: 13.4 Million Affected in Healthcare Conglomerates Privacy Crisis
2024-04-26
Mechanisms of Allograft Rejection: Insights from Behind the Scenes
2024-04-25
ImmunityBio’s ANKTIVA® Granted FDA Approval: Breakthrough IL-15 Receptor Agonist First-in-Class for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
2024-04-24
EVENT
Scroll to Top